NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Monroe AK, Gudzune KA, Sharma R, et al. Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Feb. (Comparative Effectiveness Reviews, No. 132.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Combination Therapy Versus Intensification of Statin Monotherapy: An Update

Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet].

Show details

References

1.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. [PMC free article: PMC5408511] [PubMed: 23239837]
2.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421. [PubMed: 12485966]
3.
Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44. [PubMed: 21262990]
4.
Liao Y, Bang D, Cosgrove S, et al. Surveillance of health status in minority communities - Racial and Ethnic Approaches to Community Health Across the U.S. (REACH U.S.) Risk Factor Survey, United States, 2009. MMWR Surveill Summ. 2011;60(6):1–44. [PubMed: 21597458]
5.
Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124(19):2145–54. [PMC free article: PMC3362050] [PubMed: 22064958]
6.
Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488–96. [PubMed: 7729036]
7.
Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413–9. [PubMed: 11386890]
8.
Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322(24):1700–7. [PubMed: 2342536]
9.
Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10. [PubMed: 17898099]
10.
Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol. 2000;86(12A):11L–4L. [PubMed: 11374848]
11.
Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. [PMC free article: PMC3284229] [PubMed: 19903920]
12.
Robins SJ, Collins D, Wittes JT, Papademetriou V, et al. VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation ofgemfibrozil treatment and lipid levels with major coronary events: VA-HIT: arandomized controlled trial. JAMA. 2001;285(12):1585–91. [PubMed: 11268266]
13.
Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 1977;77(1):31–6. [PubMed: 908337]
14.
Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47. [PubMed: 3513311]
15.
Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest. 1987;80(6):1692–7. [PMC free article: PMC442441] [PubMed: 3680522]
16.
Grundy SM. Consensus statement: Role of therapy with “statins” in patients with hypertriglyceridemia. Am J Cardiol. 1998;81(4A):1B–6B. [PubMed: 9526806]
17.
Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128–33. [PubMed: 8531308]
18.
Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81(4A):66B–9B. [PubMed: 9526817]
19.
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. [PMC free article: PMC2988224] [PubMed: 21067804]
20.
Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104(3):249–52. [PubMed: 11457739]
21.
Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104(4):387–92. [PubMed: 11468198]
22.
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100(3):230–5. [PubMed: 10411845]
23.
Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89(6):2519–24. [PubMed: 8205659]
24.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7. [PubMed: 7566020]
25.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22. [PubMed: 9613910]
26.
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. [PubMed: 12686036]
27.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. [PubMed: 18997196]
28.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35. [PubMed: 15755765]
29.
Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994;344(8931):1182–6. [PubMed: 7934538]
30.
Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;(1):CD004816. [PMC free article: PMC4164175] [PubMed: 21249663]
31.
Preiss D, Seshasai SR, Welsh P, Murphy SA, et al. Risk of incident diabetes withintensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64. [PubMed: 21693744]
32.
Graham DJ, Staffa JA, Shatin D, Andrade SE, et al. Incidence of hospitalized rhabdomyolysis inpatients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–90. [PubMed: 15572716]
33.
FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. [27 September 2013]. [Web Page]. Available at http://www​.fda.gov/Drugs​/DrugSafety/ucm256581.htm.
34.
Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40 Suppl 1:S53–8. [PubMed: 2044645]
35.
Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8. [PubMed: 12370217]
36.
Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2007;3(3):441–50. [PubMed: 17539750]
37.
Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1092–7. [PubMed: 12423709]
38.
Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24(8):729–41. [PubMed: 12713767]
39.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–93. [PubMed: 9808609]
40.
Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34(7):642–50. [PubMed: 3925290]
41.
Probstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med. 1994;154(14):1557–9. [PubMed: 8031204]
42.
Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154(14):1586–95. [PubMed: 8031206]
43.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–55. [PubMed: 3782631]
44.
Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98(4A):71i–6i. [PubMed: 16919519]
45.
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447–55. [PubMed: 10465168]
46.
Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circulation. 2007;115(6):700–7. [PubMed: 17283260]
47.
Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. [PubMed: 22085343]
48.
Mazze RS, Strock ES, Monk AM, et al. Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-loweringcharacteristics of colesevelam HCl (Welchol) Endocr Pract. 2013;19(2):275–83. [PubMed: 23598534]
49.
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–92. [PubMed: 11757504]
50.
Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113–22. [PubMed: 19915217]
51.
Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. [PMC free article: PMC2879499] [PubMed: 20228404]
52.
Cannon CP, Giugliano RP, Blazing MA, Harrington RA, et al. IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826–32. [PubMed: 19061694]
53.
Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43. [PubMed: 18376000]
54.
Fihn SD, Gardin JM, Abrams J, Berra K, et al. American College of Cardiology Foundation/American Heart Association Task Force. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25) [PubMed: 23166211]
55.
Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009;151(9):622–30. [PubMed: 19884623]
56.
Sharma M, Ansari MT, Soares-Weiser K, et al. Comparative Effectiveness of Lipid-Modifying Agents. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009. [Internet] 2009. [PubMed: 20704039]
57.
Tsertsvadze A, M M, Chou R, Garritty C, et al. Methods Guide for Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Jul, 2011. Comparative Effectiveness Reviews: Current Efforts in AHRQ's Effective Health Care Program. (Prepared by the University of Ottawa EPC, RAND CorporationSouthern California EPC, Oregon EPC, University of Connecticut EPC, RTIUniversity of North Carolina EPC, Johns Hopkins Bloomberg School of Public Health EPC under Contract No. 290-02-0021 EPC2). AHRQ Publication No. 11-EHC057-EF. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm. 2011.
58.
Higgins JPT, G S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. [updated March 2011] Available from www​.cochrane-handbook.org.
59.
Weng TC, Y Y, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139–51. [PubMed: 20456733]
60.
Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207–13. [PubMed: 10637210]
61.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59(1):7–10. [PubMed: 16360555]
62.
DerSimonian R, L N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
63.
Owens DK, L K, A Deal. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010;63(5):513–23. [PubMed: 19595577]
64.
Martin SS, Blaha MJ, Elshazly MB, Brinton EA. Friedewald Estimated versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. J Am Coll Cardiol. 2013:S0735–1097. [PubMed: 23524048]
65.
Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Apr, 2012. AHRQ Publication No. 10(11)-EHC063-EF. Chapters available at: www​.effectivehealthcare.ahrq.gov.
66.
Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005;149(3):464–73. [PubMed: 15864235]
67.
Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26(11):1758–73. [PubMed: 15639688]
68.
Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2125–34. [PubMed: 12505224]
69.
Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79(5):620–9. [PubMed: 15132403]
70.
Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Pehlivanidis AN, Kontopoulos AG. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk. 2002;9(1):33–9. [PubMed: 11984215]
71.
Ahmed S, Ullah E, Ahmed M, Abbas R, Khan MA, Iqbal J. Efficacy of combination of ezetimibe and simvastatin versus atorvastatin in reducing low density lipoprotein-cholesterol in male patients of hypercholesterolemia, at Bahawalpur. Medical Forum Monthly. 2008;19(5):3–9.
72.
Araujo DB, Bertolami MC, Ferreira WP, et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J Cardiovasc Pharmacol. 2010;55(1):1–5. [PubMed: 19770669]
73.
Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011;27(3):685–92. [PubMed: 21271793]
74.
Lee SH, Kang SM, Park S, Jang Y, Chung N, Choi D. The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A(2) Clin Cardiol. 2011;34(2):108–12. [PubMed: 21298654]
75.
Lee SH, Park S, Kang SM, Jang Y, Chung N, Choi D. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther. 2012;17(1):65–71. [PubMed: 21386036]
76.
Liberopoulos EN, Makariou SE, Moutzouri E, Kostapanos MS, Challa A, Elisaf M. Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels. J Cardiovasc Pharmacol Ther. 2013 [PubMed: 23288870]
77.
Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65(11):1141–8. [PubMed: 21995692]
78.
Moutzouri E, Tellis CC, Rousouli K, et al. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012;225(2):381–7. [PubMed: 23062767]
79.
Rudofsky G, Reismann P, Groener JB, et al. Identical LDL-cholesterol lowering but non-identical effects on NF-kappaB activity: High dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis. 2012;223(1):190–6. [PubMed: 22633472]
80.
Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther. 2010;15(2):167–74. [PubMed: 20147603]
81.
Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J. 2009;157(4):687.e1–8. [PMC free article: PMC3088112] [PubMed: 19332196]
82.
Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158(2):407–16. [PubMed: 11583720]
83.
Johansson J. Low-dose combination therapy with colestipol and simvastatin in patients with moderate to severe hypercholesterolaemia. 1995;5:39–44.
84.
Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409–15. [PubMed: 12719279]
85.
Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract. 2005;59(12):1377–86. [PubMed: 16351668]
86.
Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22(10):2041–53. [PubMed: 17022864]
87.
Constance C, Westphal S, Chung N, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2007;9(4):575–84. [PubMed: 17451425]
88.
Gaudiani LM, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005;7(1):88–97. [PubMed: 15642080]
89.
Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006;81(12):1579–88. [PubMed: 17165637]
90.
McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study) Atherosclerosis. 2007;192(2):432–7. [PubMed: 17239888]
91.
Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007;49(10):1035–42. [PubMed: 17349882]
92.
Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685–94. [PubMed: 18226326]
93.
Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148(3):447–55. [PubMed: 15389231]
94.
Shah HD, Parikh KH, Chag MC, et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007;12(2):91–6. [PMC free article: PMC2359602] [PubMed: 18650989]
95.
Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol. 2003;6(4):179–88. [PubMed: 14605511]
96.
Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis. 2013;12(1):9. [PMC free article: PMC3598241] [PubMed: 23374898]
97.
Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study) Cardiovasc Diabetol. 2010;9:20. [PMC free article: PMC2887787] [PubMed: 20492655]
98.
Ben-Yehuda O, Wenger NK, Constance C, et al. The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years. J Geriatr Cardiol. 2011;8(1):1–11. [PMC free article: PMC3390058] [PubMed: 22783278]
99.
Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly. Am J Cardiol. 2010;105(5):656–63. [PubMed: 20185012]
100.
Cho YK, Hur SH, Han CD, et al. Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk. Korean Circ J. 2011;41(3):149–53. [PMC free article: PMC3079135] [PubMed: 21519514]
101.
Foody JM, Brown WV, Zieve F, et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study) Am J Cardiol. 2010;106(9):1255–63. [PubMed: 21029821]
102.
Okada K, Kimura K, Iwahashi N, et al. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.- Circ J. 2011;75(10):2496–504. [PubMed: 21817821]
103.
Ostad MA, Eggeling S, Tschentscher P, et al. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis. 2009;205(1):227–32. [PubMed: 19150064]
104.
Pesaro AE, Serrano CV Jr, Fernandes JL, et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2012;158(3):400–4. [PubMed: 21334753]
105.
Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) Am J Cardiol. 2009;103(12):1694–702. [PubMed: 19539078]
106.
Tomassini JE, Mazzone T, Goldberg RB, et al. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab. 2009;11(9):855–64. [PubMed: 19508464]
107.
Hamdan R, Hajj F, Kadry Z, et al. Benefit and tolerability of the coadministration of ezetimibe and atorvastatin in acute coronary syndrome patients. J Med Liban. 2011;59(2):65–9. [PubMed: 21834489]
108.
Averna M, Zaninelli A, Le Grazie C, Gensini GF. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. J Clin Lipidol. 2010;4(4):272–8. [PubMed: 21122660]
109.
Lee JH, Kang HJ, Kim HS, Sohn DW, Oh BH, Park YB. Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial. Am J Cardiovasc Drugs. 2013 [PubMed: 23728830]
110.
Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157(1):195–203. [PubMed: 19081418]
111.
Shah HD, Parikh KH, Chag MC, et al. Beneficial effects of addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. World Heart Journal. 2008;1(1):69–77. [PMC free article: PMC2359602] [PubMed: 18650989]
112.
Barbi G, et al. Effect of Pravastatin and Cholestyramine on Triglycerids-Rich Lipoprotein Particles and Lp(a) in Patients With Type II Hypercholesterolemia. 1992;27:297–306. PMID:
113.
Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427–30. [PubMed: 2125243]
114.
Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med. 1993;153(11):1321–9. [PubMed: 8507122]
115.
Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110(5):352–60. [PubMed: 11286949]
116.
Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75(1):34–9. [PubMed: 7801861]
117.
Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93(12):1481–6. [PubMed: 15194017]
118.
Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003;91(4):418–24. [PubMed: 12586255]
119.
Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996;16(3):419–23. [PubMed: 8726600]
120.
Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. 2003;26(3):112–8. [PubMed: 12685616]
121.
Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med. 2004;164(10):1121–7. [PubMed: 15159270]
122.
Kawagoe Y, Hattori Y, Nakano A, et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J. 2011;58(3):171–5. [PubMed: 21304215]
123.
Farnier M, Steinmetz A, Retterstol K, Csaszar A. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther. 2011;33(1):1–12. [PubMed: 21397769]
124.
Guyton JR, Goldberg RB, Mazzone T, et al. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol. 2008;2(1):19–24. [PubMed: 21291711]
125.
Matsue Y, Matsumura A, Suzuki M, Hashimoto Y, Yoshida M. Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function. Circ J. 2013;77(7):1791–8. [PubMed: 23603824]
126.
Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study) Am J Cardiol. 2011;108(4):523–30. [PubMed: 21596364]
127.
Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009;204(1):208–15. [PubMed: 18996523]
128.
Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2003;91(11):1304–10. [PubMed: 12767421]
129.
Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2–5. [PubMed: 22253366]
130.
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 [PubMed: 24239923]
131.
Haynes R, Jiang L, Hopewell JC, et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013;34(17):1279–91. [PMC free article: PMC3640201] [PubMed: 23444397]
132.
Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial(IMPROVE-IT) design. Am Heart Journal. 2010 [PubMed: 20435175]
133.
Guo J, Meng F, Ma N, Li C, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012;110(9):1296–301. [PubMed: 22840347]
134.
Abramson BL, Benlian P, Hanson ME, Lin J, et al. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231hyperlipidemic patients. Lipids Health Dis. 2011;10(146) [PMC free article: PMC3180404] [PubMed: 21859459]
135.
Mikhailidis DP, et al. Comparative efficacy of the addition of ezetimibe to statin vsstatin titration in patients with hypercholesterolaemia: systematic review andmeta-analysis. Curr Med Res Opin. 27(6):1191–210. PMID: [PubMed: 21473671]
136.
Kashani A, Sallam T, Bheemreddy S, Mann DL, et al. Review ofside-effect profile of combination ezetimibe and statin therapy in randomizedclinical trials. Am J Cardiol. 2008;101(11):1606–12. [PubMed: 18489938]
137.
Mikhailidis DP, S G, B C, D G, C AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoingstatin therapy. Curr Med Res Opin. 23(8):2009–26. [PubMed: 17659159]
138.
Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in ausual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. ClinTher. 2005;27(10):1639–46. [PubMed: 16330301]
139.
Rees K, Dyakova M, Ward K, Thorogood M, Brunner E. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev. 2013. 2013. [PubMed: 23543514]
140.
Hooper L, Summerbell CD, Thompson R, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev. 2012 [PubMed: 22592684]
141.
SEARCH Collaborative Group. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-inducedmyopathy--a genomewide study. N Engl J Med. 2008;359(8):789–99. [PubMed: 18650507]
142.
Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase geneis associated with racial differences in low-density lipoprotein cholesterolresponse to simvastatin treatment. Circulation. 2008;117(12):1537–44. [PubMed: 18332269]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (4.5M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...